We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Rejects Keystone Triguard 3 Device
FDA Advisory Committee Rejects Keystone Triguard 3 Device
An FDA advisory committee concluded that Keystone Heart’s Triguard 3 cerebral embolic protection device is not substantially equivalent to a predicate device.
To View This Article:
Login
Subscribe To International Devices & Diagnostics Monitor